《大行》招商證券：翰森製藥(03692.HK)去年下半年業績超預期

阿斯達克財經

03-26

招商證券發表報告指，翰森製藥(03692.HK) 去年下半年業績超預期，受益於創新藥業務和BD合作雙輪驅動，腫瘤與抗感染板塊成主要增長引擎。營運效率持續改善，研發支出保持高位。全年分紅率42%。

該行看好阿美樂在內的核心產品的強勁增長以及自有管線的研發前景，同時翰森製藥也正在通過高效的BD合作爲其管線輸送新鮮血液。維持目標價26.5元。企業盈利能力的良好可預見性和管線研發的不斷兌現將是未來重要的估值重估催化劑。維持“增持”評級。(ha/da)(港股報價延遲最少十五分鐘。沽空資料截至 2025-03-25 16:25。)

AASTOCKS新聞

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522867525"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522867525\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522867525?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg","is_english":false,"pubTime":"2025-03-26 11:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522867525","market":"fut","top_or_hot":-1,"title":"《大行》招商證券：翰森製藥(03692.HK)去年下半年業績超預期","media":"阿斯達克財經","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/600999\">招商證券</a>發表報告指，<a href=\"https://laohu8.com/S/03692\">翰森製藥</a>(03692.HK)<span> </span>去年下半年業績超預期，受益於創新藥業務和BD合作雙輪驅動，腫瘤與抗感染板塊成主要增長引擎。營運效率持續改善，研發支出保持高位。全年分紅率42%。<br/><span></span><br/>該行看好阿美樂在內的核心產品的強勁增長以及自有管線的研發前景，同時翰森製藥也正在通過高效的BD合作爲其管線輸送新鮮血液。維持目標價26.5元。企業盈利能力的良好可預見性和管線研發的不斷兌現將是未來重要的估值重估催化劑。維持“增持”評級。(ha/da)(港股報價延遲最少十五分鐘。沽空資料截至 2025-03-25 16:25。)<br/><br/></p><div></div>AASTOCKS新聞 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行》招商證券：翰森製藥(03692.HK)去年下半年業績超預期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行》招商證券：翰森製藥(03692.HK)去年下半年業績超預期\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2025-03-26 11:46</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/600999\">招商證券</a>發表報告指，<a href=\"https://laohu8.com/S/03692\">翰森製藥</a>(03692.HK)<span> </span>去年下半年業績超預期，受益於創新藥業務和BD合作雙輪驅動，腫瘤與抗感染板塊成主要增長引擎。營運效率持續改善，研發支出保持高位。全年分紅率42%。<br/><span></span><br/>該行看好阿美樂在內的核心產品的強勁增長以及自有管線的研發前景，同時翰森製藥也正在通過高效的BD合作爲其管線輸送新鮮血液。維持目標價26.5元。企業盈利能力的良好可預見性和管線研發的不斷兌現將是未來重要的估值重估催化劑。維持“增持”評級。(ha/da)(港股報價延遲最少十五分鐘。沽空資料截至 2025-03-25 16:25。)<br/><br/></p><div></div>AASTOCKS新聞 </span> </div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1428167/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1564","symbol_name":"中資券商股","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1428167/latest-news/AAFN","article_id":"2522867525","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522867525","pubTimestamp":1742960760,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"招商證券發表報告指，翰森製藥(03692.HK) 去年下半年業績超預期，受益於創新藥業務和BD合作雙輪驅動，腫瘤與抗感染板塊成主要增長引擎。營運效率持續改善，研發支出保持高位。全年分紅率42%。該行看好阿美樂在內的核心產品的強勁增長以及自有管線的研發前景，同時翰森製藥也正在通過高效的BD合作為其管線輸送新鮮血液。維持目標價26.5元。企業盈利能力的良好可預見性和管線研發的不斷兑現將是未來重要的估值重估催化劑。維持“增持”評級。(ha/da)(港股報價延遲最少十五分鐘。沽空資料截至 2025-03-25 16:25。)AASTOCKS新聞","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600999":"招商证券","BK1564":"中资券商股","BK1589":"北水核心资产","03692":"翰森制药","BK1191":"制药","BK1147":"投资银行业与经纪业","BK0276":"资本市场","BK0012":"证金概念","BK0010":"央企","BK0188":"融资融券","BK0028":"国家队","BK1583":"高瓴概念","BK0183":"MSCI概念","06099":"招商证券"},"translate_title":"\"Big Bank\" China Merchants Securities: Hansoh Pharmaceutical (03692. HK) 's performance in the second half of last year exceeded expectations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600999":1,"03692":1,"06099":1},"content_text":"招商證券發表報告指，翰森製藥(03692.HK) 去年下半年業績超預期，受益於創新藥業務和BD合作雙輪驅動，腫瘤與抗感染板塊成主要增長引擎。營運效率持續改善，研發支出保持高位。全年分紅率42%。該行看好阿美樂在內的核心產品的強勁增長以及自有管線的研發前景，同時翰森製藥也正在通過高效的BD合作為其管線輸送新鮮血液。維持目標價26.5元。企業盈利能力的良好可預見性和管線研發的不斷兑現將是未來重要的估值重估催化劑。維持“增持”評級。(ha/da)(港股報價延遲最少十五分鐘。沽空資料截至 2025-03-25 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}